Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Overdose of aripiprazole, a new type of antipsychotic.

Carstairs SD, Williams SR.

J Emerg Med. 2005 Apr;28(3):311-3.

PMID:
15769575
2.

Atypical experience: a case series of pediatric aripiprazole exposures.

Lofton AL, Klein-Schwartz W.

Clin Toxicol (Phila). 2005;43(3):151-3.

PMID:
15902787
3.

One-year experience with aripiprazole exposures.

LoVecchio F, Watts D, Winchell J.

Am J Emerg Med. 2005 Jul;23(4):585-6. No abstract available.

PMID:
16032649
4.

Aripiprazole (abilify) overdose in a child.

Seifert SA, Schwartz MD, Thomas JD.

Clin Toxicol (Phila). 2005;43(3):193-5.

PMID:
15902794
5.

Benign clinical picture after ingestion of 780 milligrams of aripiprazole and 1050 milligrams of amitriptyline.

Prakash R, Munda S, Pattojoshi A, Choudhary PP.

Indian J Med Sci. 2009 Feb;63(2):77-80. No abstract available.

PMID:
19359772
6.

Daily dose of 105 mg aripiprazole because of delusional origin: a case report.

Wichowicz H, Wilkowska A, Landowski J.

Psychiatr Danub. 2012 Dec;24(4):400-1. No abstract available.

7.

Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.

Tadori Y, Forbes RA, McQuade RD, Kikuchi T.

Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40. doi: 10.1016/j.ejphar.2009.02.007. Epub 2009 Feb 13.

PMID:
19217900
8.

Severe extrapyramidal symptoms in a 3-year-old boy after accidental ingestion of the new antipsychotic drug aripiprazole.

Schonberger RB, Douglas L, Baum CR.

Pediatrics. 2004 Dec;114(6):1743. No abstract available.

PMID:
15574656
9.

Prolonged toxicity in a 2-year-old after accidental ingestion of aripiprazole.

Melhem S, Katz K, Jameson A, Shellenbarger D, Akhtar J.

Pediatr Emerg Care. 2009 Feb;25(2):105-6. doi: 10.1097/PEC.0b013e318196faaf.

PMID:
19225379
10.

Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.

Lu ML, Shen WW, Chen CH.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1978-81. doi: 10.1016/j.pnpbp.2008.09.016. Epub 2008 Sep 30.

PMID:
18848860
11.

[Clinical impact of aripiprazole in patients suffering from schizophrenia].

Levoyer D, Drapier D, Fadier-Salicé G, Millet B.

Encephale. 2007 May-Jun;33(3 Pt 1):332-8. French.

PMID:
17675931
12.

Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.

Keck PE Jr, McElroy SL.

Expert Opin Investig Drugs. 2003 Apr;12(4):655-62. Review.

PMID:
12665420
13.

A case of risperidone overdose in early schizophrenia: a review of potential complications.

Kopala LC, Day C, Dillman B, Gardner D.

J Psychiatry Neurosci. 1998 Nov;23(5):305-8.

14.

In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors.

Tadori Y, Forbes RA, McQuade RD, Kikuchi T.

Eur J Pharmacol. 2011 Oct 15;668(3):355-65. doi: 10.1016/j.ejphar.2011.07.020. Epub 2011 Jul 29.

PMID:
21816144
15.

The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.

Aihara K, Shimada J, Miwa T, Tottori K, Burris KD, Yocca FD, Horie M, Kikuchi T.

Brain Res. 2004 Apr 2;1003(1-2):9-17.

PMID:
15019558
16.

Cardiotoxicity associated with intentional ziprasidone and bupropion overdose.

Biswas AK, Zabrocki LA, Mayes KL, Morris-Kukoski CL.

J Toxicol Clin Toxicol. 2003;41(1):79-82.

PMID:
12645973
17.

A systematic review of cardiovascular effects after atypical antipsychotic medication overdose.

Tan HH, Hoppe J, Heard K.

Am J Emerg Med. 2009 Jun;27(5):607-16. doi: 10.1016/j.ajem.2008.04.020. Review.

18.

[Aripiprazole: a new atypical antipsychotic drug].

Fischer B, Davids E, Gastpar M.

Fortschr Neurol Psychiatr. 2004 Sep;72(9):497-502. Review. German.

PMID:
15365912
19.

Aripiprazole exposures reported to Texas poison control centers during 2002-2004.

Forrester MB.

J Toxicol Environ Health A. 2006 Sep;69(18):1719-26.

PMID:
16864422
20.

Aripiprazole acts as a selective dopamine D2 receptor partial agonist.

Wood M, Reavill C.

Expert Opin Investig Drugs. 2007 Jun;16(6):771-5. Review.

PMID:
17501690

Supplemental Content

Support Center